You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Lisata Therapeutics raises $225 million in a concurrent private placement as part of its acquisition of Marea Therapeutics. The funds will help advance clinical trials for key product candidates.
Rock Springs CapitalVen BioAffinity Asset Advisors, LlcNantahala CapitalColumbia Threadneedle InvestmentsSurveyor CapitalOmega FundsSofinnova InvestmentsPerceptive AdvisorsAlpha WaveThird Rock VenturesForbionRa Capital Management
Description
Lisata Therapeutics has announced the acquisition of Marea Therapeutics along with a concurrent financing of $225 million. This private placement financing aims to support operations and advance clinical milestones for key therapies. Leading life sciences investors participated in this oversubscribed financing. The proceeds will primarily be used to advance MAR001/005 and MAR002 through key clinical trials.
Company Information
Company
Lisata Therapeutics
Location
Cincinnati, Ohio, United States
About
Lisata Therapeutics Inc (NASDAQ:LSTA) is a pharmaceutical company that is partnering with the University of Cincinnati to investigate endometriosis therapy.
Don't miss Lisata Therapeutics's next move
Get an email the moment Lisata Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Lisata Therapeutics's next move
CincinnatiBiotechnologyHealth CareTherapeuticsPharmaceutical